NCT00376740View on ClinicalTrials.gov

Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2010

Conditions
Breast Cancer
Interventions
DRUG

zoledronic acid

Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.

Trial Locations (2)

Unknown

Soroka University Medical Center, Beersheba

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors
collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

lead

Soroka University Medical Center

OTHER

NCT00376740 - Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole | Biotech Hunter | Biotech Hunter